HTG Molecular Diagnostics Announces IVD Development Agreement with Thermo Fisher Scientific
By LabMedica International staff writers Posted on 27 Mar 2016 |
Image: The HTG Edge system which provides easy to use, walkaway automation for multiplexed profiling panels (HTG Molecular Diagnostics).
HTG Molecular Diagnostics, Inc. (Tucson, AZ, USA), a provider of instruments and reagents for molecular profiling applications, have announced that it has entered into a long-term agreement with Thermo Fisher Scientific (Waltham, MA, USA) under which HTG will have the right to develop a number of in vitro diagnostic (IVD) tests for use with Thermo Fisher’s next-generation sequencing Ion PGM Dx System.
In 2013 HTG Molecular Diagnostics commercialized its HTG Edge instrument platform and a portfolio of ribonucleic acid (RNA) assays that leverage HTG's proprietary nuclease protection chemistry. HTG's product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing.
HTG EdgeSeq system automates their novel target capture and library preparation chemistry and helps enable fast and easy use of next-generation sequencers (NGS) for microRNA (miRNA), messenger RNA (mRNA), fusions, and DNA analysis. HTG EdgeSeq system simplifies library and sample preparation for targeted sequencing enhancing productivity and ease of use. HTG EdgeSeq extraction-free chemistry also can significantly reduce sample input requirements, especially from formalin-fixed, paraffin embedded (FFPE) samples.
Timothy (TJ) B. Johnson, BS, President and Chief Executive Officer at HTG, said, “We believe the combination of HTG EdgeSeq chemistry and automation platform with the Ion Torrent next-generation sequencing (NGS) platform is a great solution for clinical sequencing workflows in molecular diagnostic laboratories. We believe this agreement will provide us important options for our planned diagnostic menu.”
Related Links:
HTG Molecular Diagnostics
Thermo Fisher Scientific
In 2013 HTG Molecular Diagnostics commercialized its HTG Edge instrument platform and a portfolio of ribonucleic acid (RNA) assays that leverage HTG's proprietary nuclease protection chemistry. HTG's product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing.
HTG EdgeSeq system automates their novel target capture and library preparation chemistry and helps enable fast and easy use of next-generation sequencers (NGS) for microRNA (miRNA), messenger RNA (mRNA), fusions, and DNA analysis. HTG EdgeSeq system simplifies library and sample preparation for targeted sequencing enhancing productivity and ease of use. HTG EdgeSeq extraction-free chemistry also can significantly reduce sample input requirements, especially from formalin-fixed, paraffin embedded (FFPE) samples.
Timothy (TJ) B. Johnson, BS, President and Chief Executive Officer at HTG, said, “We believe the combination of HTG EdgeSeq chemistry and automation platform with the Ion Torrent next-generation sequencing (NGS) platform is a great solution for clinical sequencing workflows in molecular diagnostic laboratories. We believe this agreement will provide us important options for our planned diagnostic menu.”
Related Links:
HTG Molecular Diagnostics
Thermo Fisher Scientific
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance